[HTML][HTML] A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy

C Mazzaro, L Quartuccio, LE Adinolfi, D Roccatello… - Viruses, 2021 - mdpi.com
Extrahepatic manifestations are a feature of chronic hepatitis C virus (HCV) infection. In the
course of chronic HCV infection, about 70% of patients have one or more extrahepatic …

[HTML][HTML] Estimates of the global burden of cervical cancer associated with HIV

D Stelzle, LF Tanaka, KK Lee, AI Khalil… - The lancet global …, 2021 - thelancet.com
Background HIV enhances human papillomavirus (HPV)-induced carcinogenesis. However,
the contribution of HIV to cervical cancer burden at a population level has not been …

[HTML][HTML] Burden, Outcome, and comorbidities of Extrahepatic manifestations in Hepatitis C virus Infection

B Songtanin, K Nugent - Biology, 2022 - mdpi.com
Simple Summary Hepatitis C is a liver infection caused by the hepatitis C virus and is a
major health problem that contributes to the global burden of chronic disease. Chronic …

[HTML][HTML] Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral …

S Ballestri, A Mantovani, E Baldelli, S Lugari… - Diagnostics, 2021 - mdpi.com
Liver fibrosis predicts liver-related and cardiovascular outcomes in chronic liver disease
patients. We compared the diagnostic performance of various liver fibrosis biomarkers for …

Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study

LE Adinolfi, S Petta, AL Fracanzani, C Coppola… - Atherosclerosis, 2020 - Elsevier
Background and aims HCV is associated with an increased risk of cardiovascular events
(CV). Whether HCV clearance by direct-acting antivirals (DAA) reduces incident CV disease …

Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

GTS Guerreiro, L Longo, MA Fonseca… - Hepatology …, 2021 - Springer
Background/purpose Cardiovascular disease (CVD) is the leading cause of death among
individuals with non-alcoholic fatty liver disease (NAFLD). Recently, NAFLD was renamed …

[HTML][HTML] Trends of the global hepatitis C disease burden: strategies to achieve elimination

N Brunner, P Bruggmann - Journal of preventive medicine and …, 2021 - ncbi.nlm.nih.gov
Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as
for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is …

Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

FC Sasso, PC Pafundi, A Caturano, R Galiero… - Nutrition, Metabolism …, 2021 - Elsevier
Background and aims Beyond type 2 diabetes, even a condition of prediabetes is
associated with an increased cardiovascular (CV) risk, and HCV infection coexistence …

[HTML][HTML] Global and regional estimate of HIV-associated stroke burden: a meta-analysis and population attributable modeling study

Y Yang, X Yao, Y Liu, J Zhao, P Sun, Y Zhang, K Li… - Stroke, 2023 - journals.lww.com
BACKGROUND: This study aimed to determine the correlation between human-
immunodeficiency-virus (HIV) infection and stroke, as well as to estimate the global …

[HTML][HTML] Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases

N Perakakis, H Harb, BG Hale, Z Varga… - The Lancet Diabetes & …, 2023 - thelancet.com
Viruses have been present during all evolutionary steps on earth and have had a major
effect on human history. Viral infections are still among the leading causes of death. Another …